ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
Status:
Completed
Trial end date:
2021-10-23
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and tolerability in healthy overweight and
obese volunteers administered single or multiple repeated doses of ALT-801.
This study has 2 parts. Part 1 involves a single dose of ALT-801 taken as a subcutaneous (SC)
injection and will be approximately 36 days in duration. Part 2 involves 12 doses of ALT-801,
once a week for 12 weeks, as a SC injection and will be approximately 116 days in duration.
Each participant will enroll in only one part.